<table>
<thead>
<tr>
<th>Recorded Program Times</th>
<th>Opening Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0:00 – 0:05</td>
<td>Slide 1</td>
</tr>
</tbody>
</table>
| 0:05 – 0:23            | Bonnie Henry, MD MPH  
Deputy Provincial Health Officer, British Columbia Ministry of Health and  
Associate Professor, School of Population and Public Health  
Faculty of Medicine, UBC  
Overview of the current Ebola situation in W. Africa and Medical Health Officer coordination efforts for Canadian preparations |
| Slides 2-23             | |
| 0:23 – 1:38            | Xiangguo Qiu, MD MSc  
Head of Serology Diagnostics Unit in Special Pathogens  
National Microbiology Laboratory, Public Health Agency of Canada  
Monoclonal antibodies contributing to ZMapp |
| Slides 24-83           | |
| 1:38 – 2:24.5           | Ian MacLachlan, PhD  
Executive Vice President and Chief Technical Officer  
Tekmira Pharmaceuticals Corporation  
Investigational TKM-Ebola Therapeutic |
| Slides 84-123          | |
| 2:24.5 – 2:35          | Christopher Lowe, MSc MD FRCPC  
Medical Microbiologist  
Infection Prevention and Control Physician, Providence Health Care  
Infection control preparedness in BC |
| Slides 124-136         | |
| 2:35 – 2:42            | Steve Kanters, PhD(c) MSc  
Research Associate, Centre for Clinical Epidemiology and Evaluation  
and Research Manager and Statistician, Global Evaluative Sciences  
Methods of fast-tracking clinical trials for Ebola |
| Slides 137-148         | |
| 2:42 – 2:48            | Jan Hajek, MD FRCPC  
Clinical Assistant Professor, Division of Infectious Diseases  
Department of Medicine, Faculty of Medicine, UBC  
Physician experience in a treatment centre in Guinea |
| Slides 149-163         | |
| 2:48 – 2:54.5          | Stephanie N Parent, BSc MPH(c)  
WHO Collaborating Centre for Occupational and Environmental Health  
School of Population and Public Health, Faculty of Medicine, UBC  
Current Ebola projects in collaboration with WHO |
| Slides 164-193         | |
| 2:54.5 – 3:02          | Srinivas Murthy, MD CM FAAP FRCPC  
Clinical Assistant Professor, Critical Care  
Department of Pediatrics, Faculty of Medicine, UBC  
WHO National Lead, Liberia - coordination efforts |
| Slides 193-206         | |
| 3:02 – 3:31            | Panel Question and Answer Session |
| Slides 207-217         | |
| 3:31 – 3:37            | Closing comments |
Keynote Speaker Biographies

**Xiangguo Qiu, MD MSc**

Dr. Xiangguo Qiu received her M.D. degree in 1985 at Hebei Medical University and M.Sc. in immunology in 1990 at Tianjin Medical University. She went to MD Anderson Cancer Center (USA) as a visiting Scientist in 1996 and moved to Cancer Care Manitoba (Canada) in 1997 as a research associate. In 2003, she joined the Special Pathogens Program at the National Microbiology Laboratory at the Public Health Agency of Canada to start studying the most deadly viruses, such as Ebola/ Marburg/Lassa, in the only level 4 (highest containment level) laboratory in Canada. Her primary field is immunology with research emphasis on vaccine development, post-exposure therapeutics and rapid diagnostic of haemorrhagic viruses. As a member of WHO expert team, she and her colleagues provided advises/technical support for biosafety in 2008 Beijing Olympics, 2010 Shanghai Expo, 2010 Asian games in Guangzhou, 2010 winter Olympics in Vancouver and G8/G20 in Toronto, Canada. Her group has first demonstrated that mAbs completely protect nonhuman primates from *Ebola virus* infection in the filovirus field. Moreover, she and colleagues have developed ZMapp which has been compassionately used in several Ebola infected patients and showed very promising outcomes. Currently, Dr. Qiu leads Serology Diagnostics Unit in Special Pathogens Program of National Microbiology Laboratory, Public Health Agency of Canada.

**Ian MacLachlan, PhD**

Dr. MacLachlan has served as Tekmira’s Executive Vice President and Chief Technical Officer since May 2008, when Dr. MacLachlan joined Tekmira in connection with the closing of the business combination between Tekmira and Protiva. Dr. MacLachlan was a co-founder of Protiva in 2000 and led Protiva’s R&D program since the company’s inception. A graduate of the University of Alberta, where he received both his B.Sc. and Ph.D. in Biochemistry, Dr. MacLachlan spent two years at the Vienna Bio-Center where some of the first experiments in systemic gene delivery were performed. Following this, Dr. MacLachlan conducted postdoctoral research at the Howard Hughes Medical Institute at the University of Michigan in the laboratory of Dr. Gary Nabel, a pioneer in the development of DNA-based therapeutics. Active in molecular therapeutics for more than a decade, he co-founded Protiva after five years leading the development of the gene transfer technology at Inex Pharmaceuticals. Dr. MacLachlan has been an invited speaker on nucleic acid delivery at the National Institutes of Health, the National Cancer Institute, numerous academic institutions and most major scientific meetings dealing with molecular therapy. He is a member of the New York Academy of Sciences, the Oligonucleotide Therapeutics Society and the American Society of Gene Therapy and serves on the Editorial Board of the journals Molecular Therapy and Oligonucleotides.

Panel Members

**Bonnie Henry, MD, MPH**

Dr. Bonnie Henry was appointed as Deputy Provincial Health Officer for the Province of BC effective August 5, 2014. She was previously the interim Provincial Executive Medical Director of the BC Centre for Disease Control and the Medical Director of Communicable Disease Prevention and Control and Public Health Emergency Management with the BC Centre for Disease Control and Medical Director for the provincial Emerging and Vector-borne Diseases program. In 2003 she was the operational lead in the response to the SARS outbreak in Toronto. She was a member of the executive team of the Ontario SARS Scientific Advisory Committee. Dr. Henry worked with the WHO/UNICEF Polio eradication program in Pakistan in 2000 and with the World Health Organization to control the Ebola outbreak in Uganda in 2001.

**Christopher Lowe, MSc MD FRCP**

Dr. Lowe attended medical school at the University of British Columbia, and subsequently completed his residency in Medical Microbiology at the University of Toronto. His research interests are focused on identifying optimal methods for infection control of multi-drug resistant gram-negative organisms and hospital-acquired infections. He is a staff Medical Microbiologist and Infection Prevention and Control Physician at Providence Health Care. He is also currently a member of the Expert Clinical Group (Laboratory and Infection Control sub-committees) of the BC Provincial Ebola Task Force.

**Steve Kanters, PhD(c), MSc**

Mr. Kanters has conducted global health research in infectious and non-communicable diseases in sub-Saharan African settings since 2008. He is formally trained in epidemiology and statistics. He is currently involved with clinical trials in Uganda, Rwanda, and South Africa. He is a Research Associate at the Centre for Clinical Epidemiology and Evaluation at the University of British Columbia, and a Research Manager and Statistician at Global Evaluative Sciences. He has over 30 peer-reviewed publications in high impact journals.

**Jan Hajek, MD, FRCP**

Jan Hajek is an infectious diseases doctor currently based at Vancouver General Hospital. He has a special interest in TB and tropical diseases. He has previously worked with Doctors with Borders (MSF) in Uzbekistan an South Sudan. This past September he worked with MSF in Gueckedou, Guinea, assisting with the clinical care at an Ebola Treatment Centre. He is returning to West Africa in November to work with WHO as a clinical trainer.

**Stephanie N. Parent, BSc MPH(c)**

Stephanie N. Parent, B.Sc, is a Master’s of Public Health student at the University of Victoria and a research assistant working in the Global Health Research Program (GHRP) in the School of Population and Public Health at UBC. The GHRP is a WHO Collaborating Centre in Occupational and Environmental Health and, as such, was invited to consult with the WHO on the Ebola emergency response.

**Srinivas Murthy, MD CM FAAP FRCP**

Srinivas Murthy is assistant professor in the division of critical care at BC Children’s Hospital. He graduated from McGill University Medical School in 2006, did his residency in at Boston Children’s Hospital, and fellowship training at the Hospital for Sick Children. He joined the faculty at the University of British Columbia in 2013. He is board-certified in infectious diseases and critical care. His research interests are in the management of severe infections in children.